IP Library Granted Patent US 7,993,866
Granted Patent B2
US 7,993,866 · App. 12/352,578 · Granted Aug 9, 2011

Diagnosis, prevention and treatment of crohn's disease using the OmpC antigen

Assignees: Cedars-Sinai Medical Center; The Regents of the University of California
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,993,866
App. No.
12/352,578
Granted
Aug 9, 2011
Kind
B2
Abstract

The present invention provides a method of diagnosing Crohn's disease in a subject by determining the presence or absence or IgA anti-OmpC antibodies in the subject, where the presence of the IgA anti-OmpC antibodies indicates that the subject has Crohn's disease.

Claims (16)

1. A method for performing an assay for improving the diagnosis of Crohn's disease, said method comprising:

(a) contacting a patient's sample containing IgA anti-outer membrane protein antibodies (anti-OmpC antibodies) with an OmpC antigen, or reactive fragment thereof to form a complex between the OmpC antigen or reactive fragment thereof and the IgA anti-OmpC antibodies;

(b) contacting the sample from step (a) with an enzyme-labeled anti-IgA antibody to form a labeled complex;

(c) contacting the sample from step (b) containing a labeled complex with an enzyme substrate; and

(d) analyzing the sample from step (c) for the presence or absence of the labeled complex using a spectrophotometer, wherein the analysis detects the labeled complex, to improve the diagnosis of Crohn's disease.

2. The method of claim 1 , wherein said patient's sample is human serum.

3. The method of claim 1 , wherein said OmpC antigen comprises the amino acid sequence of SEQ ID NO: 1 or 90% identity thereof.

4. The method of claim 1 , wherein said assay is performed on an assay system, said assay system comprising:

(a) a plate device comprising an OmpC antigen, or reactive fragment thereof, wherein said OmpC antigen comprises the amino acid sequence of SEQ ID NO:1 or 90% identity thereof;

(b) an indicator secondary antibody specific for an OmpC autoantibody, wherein said indicator secondary antibody is an enzyme-labeled anti-IgA antibody; and

(c) instructions for detecting the presence or absence of a complex of said OmpC antigen, said OmpC autoantibody, and said indicator secondary antibody.

5. The method of claim 4 , wherein said plate device further comprises a control.

6. The method of claim 4 , wherein said system further comprises a substrate for said enzyme-labeled antibody.

7. The method of claim 6 , wherein said substrate is transformed to a product, wherein said product is chromogenic.

8. The method of claim 4 , wherein said OmpC antigen comprises the amino acid sequence of SEQ ID NO: 1.

9. The method of claim 1 , wherein said assay is performed to facilitate earlier and appropriate treatment for Crohn's Disease patients.

Assignments (3)
CONFIRMATORY LICENSE Recorded Sep 20, 2010
From: UNIVERSITY OF CALIFORNIA LOS ANGELES
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025010/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2010
From: TARGAN, STEPHAN R.
To: CEDARS-SINAI MEDICAL CENTER
Reel/Frame 024309/0586 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 29, 2010
From: BRAUN, JONATHAN; SUTTON, CHRISTOPHER L.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 024309/0738 →
Continuity (3)
Continuation 11561024 · Nov 17, 2006
Continuation 09575061 · May 19, 2000
Related Publication 20090221006A1 · Sep 3, 2009